Agenus Inc. disclosed the results of an investigator‑initiated Phase II study conducted at Memorial Sloan Kettering Cancer Center, in which the combination of botensilimab (BOT) and balstilimab (BAL) was paired with the MiNK allo‑iNKT cell therapy agenT‑797, ramucirumab, and paclitaxel in patients with advanced PD‑1 refractory gastroesophageal adenocarcinoma. The data, presented at the American Association for Cancer Research (AACR) 2026 meeting, showed durable survival benefits and immune reprogramming, with improved overall survival and objective response rates compared with historical controls for this refractory disease.
The study enrolled heavily pre‑treated patients and demonstrated a 77 % disease‑control rate and long‑term survival beyond 20 months in a subset of participants. These findings represent a significant clinical milestone for Agenus, reinforcing the company’s strategy to advance the BOT/BAL combination into larger, pivotal trials and to broaden its indication to other PD‑1 refractory malignancies. The combination is a core product candidate for colorectal and other solid tumors, and the Phase II data provide a strong foundation for future regulatory submissions.
Vice President of Research Dhan Chand noted, “These findings illustrate the mechanistic synergy of agenT‑797 with botensilimab and balstilimab in this PD‑1 refractory setting. The induction approach promoted significant intratumoral infiltration of T cells and dendritic cells, the formation of organized tertiary lymphoid structures in on‑treatment biopsy tissue from a patient with durable benefit, and activation of peripheral CD4 and CD8 T‑cell populations.”
Agenus’ recent Q4 2025 earnings beat—$0.56 EPS versus a $‑1.27 estimate—and $34.2 million in revenue, combined with a Zydus collaboration that provided a substantial upfront payment, have bolstered investor confidence. Analyst upgrades, including a “buy” rating from Wall Street Zen and a Zacks Rank #1 (Strong Buy), further amplified the positive market reaction to the clinical data. The company’s ability to deliver a clinically meaningful result in a difficult-to-treat population signals strong execution and positions the BOT/BAL program for accelerated development.
The positive Phase II data, coupled with the company’s recent financial performance and analyst support, suggest that Agenus is on a trajectory to strengthen its pipeline and improve its financial outlook. The results provide a compelling rationale for the company’s planned expansion of the BOT/BAL combination into Phase III trials and for exploring additional PD‑1 refractory indications.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.